Atara Biotherapeutics, Inc. Appoints Eric Dobmeier, Chief Operating Officer of Seattle Genetics, Inc., to Its Board of Directors Mar 27, 2015 6:30am EDT
Atara Biotherapeutics' Collaborating Investigators to Present Clinical Data on T-Cell Therapy for EBV Lymphoma at a Clinical Trials Plenary Session at the American Association for Cancer Research Annual Meeting 2015 Mar 19, 2015 6:30am EDT
FDA Grants Breakthrough Therapy Designation to Epstein-Barr Virus (EBV) Targeted T-Cells for Treatment of EBV-Associated Lymphoproliferative Disease Mar 02, 2015 6:30am EST
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2014 Operating Results Feb 26, 2015 4:05pm EST
Atara Biotherapeutics Announces Closing of Underwritten Offering of Common Stock and Exercise of Underwriters' Option to Purchase Additional Shares Feb 18, 2015 4:21pm EST
